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Incidence
The incidence of AFE varies significantly in different reports worldwide. This is because non-uniform criteria and different methods of collecting data, such as hospital coding rather than clinical reporting, exist in different countries.
Between 2005 and 2014, there were 120 confirmed cases of AFE in the UKOSS register, which gives an incidence of 1.7 per 100,000 maternities and a case fatality of 19%. 2 A recent systematic review by Frati and colleagues compared nine studies, and found a mean incidence of 5.5 per 100,000 pregnancies (range: 2e15.2) and a mean case fatality rate of 24.8% (range: 13.3e48%). 3 In the last MBRRACE-UK report, AFE was shown to be the fifth direct cause of maternal mortality preceded by thromboembolism, haemorrhage, suicide, and pregnancyrelated sepsis. 4 
Risk factors
Many factors have been identified as possible risk factors, but none have been proved categorically. There is strong evidence
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Key points
Amniotic fluid embolism is still a leading cause of maternal mortality.
There is a temporal relationship between the two proposed pathophysiological theories: mechanical and immunological. The clinical picture is non-specific, but hypotension and fetal distress have been identified in all cases. Many laboratory tests are helpful in guiding management, but none is proved to aid diagnosis at the time. Management should not be delayed where the diagnosis is difficult or by exclusion.
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that induction of labour by any method increases the risk of AFE. 5 The use of oxytocin for induction or augmentation of labour has been associated with an increased incidence, especially if hyper-stimulation occurred. 2, 5 In the postdelivery period, assisted delivery (forceps or ventouse) and Caesarean section have been identified to increase the risk.
Other factors suggested to increase the risk of AFE are maternal age >35 yr, male fetus, multiple pregnancy, polyhydramnios, eclampsia, uterine rupture, cervical trauma, placenta praevia, placental abruption, and ethnic minority. Whilst each of these individual risk factors is common, the incidence of AFE is rare, which leads to the conclusion that AFE is quite unpredictable.
Pathogenesis
It is hypothesised that exposure of the maternal circulation to amniotic fluid or fetal antigens is a prerequisite for AFE to occur. This can follow events that lead to open vessels coming into contact with amniotic fluid: uterine trauma, cervical trauma, or trauma of the utero-placental unit. Although exposure to amniotic fluid happens during normal labour or surgical delivery, the exact mechanism in these situations leading to clinically significant AFE remains unclear. Many women will be exposed to amniotic fluid and fetal material, but will not show any signs of AFE, so there may be some inherent susceptibility.
There are two main theories for the mechanism of AFE: mechanical and immune mediated. Either of them explains the pathogenesis only partially when used on their own, but when combined will give a more complete picture.
Mechanical theory
Amniotic fluid contains fetal squamous cells, vernix caseosa, lanugo, trophoblasts, fetal gut mucin, and bile-stained meconium. Whilst some of the presentations could suggest a mechanical element to a large bolus of amniotic fluid, it is mostly thought to be a response to the fluid and material that passes into the maternal circulation. Therefore, some authors describe AFE as an anaphylactoid syndrome.
Immune-mediated theory
Currently, it is thought that AFE results from immunological activation secondary to exposure to fetal antigens. This theory emerged initially from the similarities between AFE, systematic inflammatory response syndrome, and anaphylaxis. The amniotic fluid itself contains numerous immunologically active and prothrombotic substances, including plateletactivating factor, interleukins, complement factors, and tumour necrosis factor-alpha.
Mast-cell degranulation, which occurs on exposure to fetal antigens, is similar to that in anaphylaxis, but studies have Clinical scenario 1 A woman was induced at term. Shortly aŌer an epidural top-up she became hypotensive, breathless and dizzy, then cyanosed and had a cardiac arrest. Intralipid® was given to counteract possible local anaestheƟc toxicity. She was delivered by Caesarean secƟon in the delivery room whilst CPR conƟnued. She developed pulmonary oedema and disseminated intravascular coagulaƟon. She had intensive surgical and medical management of haemorrhage. She was transferred to intensive care for mulƟple organ support unƟl care was withdrawn aŌer confirmaƟon of irrecoverable brain injury. The absence of seizure or ventricular arrhythmia, coupled with the nature of her clinical presentaƟon followed by the onset of massive haemorrhage and DIC, and the postmortem finding of fetal squames in the pulmonary circulaƟon were in keeping with the final diagnosis of AFE.
Clinical scenario 2
A woman was admiƩed for inducƟon of labour for postmaturity. Shortly aŌer a vaginal examinaƟon to confirm spontaneous rupture of membranes she complained of feeling unwell and collapsed. Full CPR was not iniƟated for over 20 min; she was delivered by Caesarean secƟon in theatre aŌer a further 20 min. ResuscitaƟon, involving a hysterectomy for major obstetric haemorrhage and subsequent further exploratory laparotomy, conƟnued for several hours. Fetal squames were found in the lung, heart, and kidneys at a post-mortem as well as extensive cerebral infarcƟon.
Clinical scenario 3
A mulƟparous woman was admiƩed post term with spontaneous rupture of membranes and meconium stained liquor. A syntocinon infusion was started as she was in early labour. Within an hour she was contracƟng strongly and began involuntary pushing. The fetal heart rate dropped, she became distressed and breathless, then cyanosed and unresponsive with seizure acƟvity. She had an emergency Caesarean secƟon under general anaesthesia. Although records did not idenƟfy cardiac or respiratory arrest during the acute collapse, she died several days later aŌer brain-stem death was confirmed.
Reproduced with permission from Knight M et al. failed to show a significant increase in serum mast-cell tryptase after AFE. A possible explanation is the fact that mast cells degranulate mostly in the lungs, and therefore, the tryptase concentrations are not raised in the systemic circulation. Another suggested trigger for mast-cell degranulation is complement activation. Reduced concentrations of C3 and C4 in AFE, in conjunction with the presence of respiratory distress, make it highly likely that complement has an important role in the pathophysiology. 6, 7 In addition, the activation of the coagulation cascade supports the immunological theory. This is not entirely understood, but the presence of tissue factor and plateletactivating factor, and complement activation, may have a role in the development of DIC.
There is a temporal relationship between the two main pathophysiological theories. Phase 1 can last about 30 min and is thought to follow the initial entry of amniotic fluid into the circulation. The pulmonary artery pressure rises, and right ventricular failure ensues with subsequent microvascular damage and hypotension. Pulmonary obstruction can be exacerbated by the formation of microthrombi in the pulmonary vasculature once DIC has developed. Phase 2 occurs in patients who survive the initial insult, and is characterised by left ventricular failure, endothelial activation and leakage, and DIC.
Clinical features
The clinical examples presented in Figure 1 represent some of the common clinical situations where AFE is the cause of maternal death. 8 About 70% of cases occur during labour, 19%
during Caesarean delivery, and 11% in the immediate period after vaginal delivery. 9 The most common signs and symptoms that have been identified in all cases are hypotension and acute fetal compromise (when AFE occurred before delivery) ( Table 1) . A large number of patients presented with sudden cardiovascular collapse or cardiac arrest (87%). Women presenting with cardiac arrest are more likely to die or have permanent hypoxic brain injury than those who presented with other initial features. 2 In the surviving group, the most common cardiovascular feature is ongoing left ventricular failure without significant pulmonary hypertension. The presence of meconium in the amniotic fluid is shown to increase the likelihood of developing left ventricular failure. The respiratory system is compromised in the initial phase of AFE by evolving adult respiratory distress syndrome (ARDS) or pulmonary oedema, observed in 93% of cases. Bronchospasm, dyspnoea and coughing are less common initial presentations. Ventilator-associated pneumonia may be a complication in critical care.
Another main feature of the clinical presentation of AFE is coagulopathy. It is observed in 83% of patients, and in rare cases can be the sole feature of AFE. Consumptive coagulopathy and DIC may lead to the need for hysterectomy and massive transfusions of blood products and clotting factors.
In the critical care setting, patients with AFE may develop the consequences of multiorgan failure. Babies born to women who had AFE are at increased risk of hypoxic ischaemic encephalopathy and cerebral palsy.
Diagnosis
The diagnosis of AFE is mainly clinical and is essentially a diagnosis by exclusion. The UKOSS has set out diagnostic criteria, which are used in the national registry (Fig. 2) .
Numerous laboratory tests have been proposed and studied in the context of AFE. None of them are specific enough for In the absence of any other clear cause the diagnosis of AFE is made by:
Either Acute maternal collapse with one or more of the following features:
• Premonitory symptoms (e.g. restlessness, numbness, agitaƟon, Ɵngling)
• Seizure • Shortness of breath Excluding women with maternal haemorrhage as the first presenƟng feature in whom there was no evidence of early coagulopathy or cardio-respiratory compromise Or Women in whom the diagnosis was made at post-mortem examinaƟon with the finding of fetal squames or hair in the lungs making the diagnosis, but they can still aid and guide management.
Standard tests, including full blood count, liver and renal function tests, electrolytes and arterial blood gases do not aid in diagnosis, but remain useful in management. Coagulation studies will demonstrate low fibrinogen with prolonged prothrombin and partial thromboplastin times, whereas thrombocytopaenia is a rare finding initially. Thromboelastography may support diagnosis and should be used whenever available. Arterial blood gases will almost inevitably show hypoxaemia and changes in acidebase balance.
Electrocardiogram may show sinus tachycardia, bradycardia, various dysrhythmias, right ventricular strain, and STsegment and T-wave changes. Recently, transthoracic and transoesophageal echocardiography have been used to aid in diagnosis. Reported findings are acute right ventricular failure, severe pulmonary hypertension, and a cavity-obliterated left ventricle during the early phase of AFE. Occasionally, intracardiac thrombi or emboli can be seen.
Multiple biomarkers have been suggested to increase the likelihood of AFE diagnosis in conjunction with the clinical features. The complement fractions, C3 and C4, have been found to be low in patients with AFE. Other pre-existing causes of massive complement activation, which occurs in some autoimmune conditions, should be excluded. The components of meconium and amniotic fluid, such as zinc coproporphyrin and Sialyl-Tn antigen, have now been shown to have high sensitivity and specificity in small studies. These tests are not widely available, which, in conjunction with the rarity of AFE, makes them impractical, and they have mainly research value. Mast-cell degranulation leads to increased serum tryptase and histamine concentrations in urine, both of which can be quantified. Unfortunately, neither of them has proved useful in making the diagnosis of AFE.
Recently, insulin-like growth-factor-binding protein-1 (ILGFBP-1) has been proposed as a valuable biomarker aiding in the diagnosis of AFE.
11 ILGFBP-1 is a protein synthesised in the placental decidua, and its concentration is about 150 times higher in the amniotic fluid than in maternal circulation. It is suggested that its reliability as a confirmatory test is augmented by testing in conjunction with alpha-fetoprotein and fetal fibronectin. 6 Lastly, the histological diagnosis of AFE can be made, although findings are not pathognomonic, as they can occur in other settings. Fetal squames and hair can be found in postmortem histological samples from lungs, kidneys, brain, liver, and spleen. Similar findings can be seen in films of pulmonary artery blood, but differentiating between maternal and fetal cells can be difficult. Resuscitation efforts may act to dilute the amount of fetal material in the mother and make detection more difficult at post-mortem. Therefore, clinical correlation remains necessary in the diagnosis of AFE.
Differential diagnosis
AFE is a diagnosis of exclusion, and the possible differential diagnoses can be divided into obstetric and non-obstetric (Table 2) .
Management
The treatment of AFE is entirely supportive. Management depends on clinical presentation and whether the fetus is delivered or not. Senior clinicians must be involved in AFE cases (obstetrician, anaesthetist, haematologist, intensivist, senior midwife, and neonatologist). An urgent decision to deliver may be needed and rapid critical care support should be mobilised.
Management should always start with a systematic assessment as recommended in the current advanced life support (ALS) guidelines.
Airway and breathing
In mild cases, high-flow oxygen delivered via a nonrebreathing mask may suffice. In more severe cases, oxygenation and ventilation should be achieved by early tracheal intubation, particularly in labour because of increased risk of aspiration. After the initial resuscitation, ventilation should follow recommendations for lung-protective therapy in intensive care.
Cardiovascular instability
Cardiovascular instability should be managed with fluids, vasopressors, and inotropic agents. The usual first-line agents are a-adrenergic receptor agonists [phenylephrine or mixed aand b-adrenergic agonists (metaraminol, ephedrine, and adrenaline)] given peripherally. Once central venous access has been secured, more-potent agents (noradrenaline, dobutamine, and milrinone) may be added as required. Early establishment of invasive monitoring, including cardiac output monitoring, is desirable. Echocardiography may aid in cardiovascular assessment.
In the case of cardiac arrest, resuscitation should occur as soon as recognised, according to ALS guidelines. Displacement of the pregnant uterus must be maintained throughout. If maternal cardiac output does not return after two cycles of cardiac compressions (4 min), perimortem evacuation of the uterus must be performed by the fifth minute to aid in maternal resuscitation and improve the survivability of the fetus.
Intra-aortic balloon counter-pulsation, cardiopulmonary bypass, and extracorporeal membrane oxygenation have all been reported as therapeutic strategies in centres where they are easily available.
Haemorrhage control
Uterine tone should be managed as usual with oxytocin, ergometrine, and prostaglandins. Bimanual uterine massage 
Coagulation abnormalities
Coagulation abnormalities and haemorrhage occur frequently and must be managed early. Activation of a massive obstetric haemorrhage protocol and transfusion of blood products should follow local guidelines. Hypofibrinogenaemia is a common finding and requires management with fibrinogen concentrates or cryoprecipitate. Anti-fibrinolytic agents, such as tranexamic acid, have recently been shown to reduce mortality in postpartum haemorrhage. 12 Recombinant factor VIIa has also been reported to reduce blood loss, but is occasionally associated with massive intravascular thrombosis.
Haematological opinion and frequent monitoring of coagulation and point-of-care testing, such as thromboelastography, should guide further management.
Outcomes
Despite being a rare condition, AFE remains a leading cause of maternal death. The long-term morbidity amongst survivors has been shown to improve because of early recognition, prompt initial management, and better critical care. Neonatal mortality has been reported to be as high as 40%, but, in keeping with improved maternal outcomes, this might also decrease. However, further analysis into neonatal outcomes is required. It is still unknown if women who survived AFE are at increased risk of the condition in subsequent pregnancies.
Conclusion
AFE remains a rare cause of maternal mortality and morbidity. Outcomes are improving significantly as a result of increased awareness of the condition and expedient management of these women. Despite availability of numerous biomarkers and advances in research, the diagnosis remains clinical and management is largely supportive.
Declaration of interest
None declared.
MCQs
The associated MCQs (to support CME/CPD activity) will be accessible at www.bjaed.org/cme/home by subscribers to BJA Education.
